Clearly, options traders are pricing in a big move for Supernus Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Supernus Pharmaceuticals is a Zacks Rank #3 ...

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 4.14M to 3.97M. This put 10.76% of the company's publicly available shares short.

Who is Krishna Kittu Kolluri? Krishna Kittu Kolluri has an estimated net worth of $5.76 Million. This is based on reported shares across multiple companies, which include TESARO, Inc., OPOWER, INC ...

Purpose: The antiemetic effectiveness of ondansetron 8 mg i.v., ondansetron 32 mg i.v., and granisetron 10 µg/kg or 1 mg i.v. as prophylaxis in breast cancer patients receiving cyclophosphamide ...

Objectives: This study aimed to identify, measure and evaluate expected costs of innovative palonosetron-based antiemetic therapy versus ondansetron-based treatment, the ultimate aim being to ...